Agios PharmaceuticalsAGIO
About: Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.
Employees: 488
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
75% more first-time investments, than exits
New positions opened: 42 | Existing positions closed: 24
20% more repeat investments, than reductions
Existing positions increased: 84 | Existing positions reduced: 70
8% more funds holding
Funds holding: 205 [Q3] → 222 (+17) [Q4]
0.07% less ownership
Funds ownership: 104.94% [Q3] → 104.87% (-0.07%) [Q4]
22% less call options, than puts
Call options by funds: $9.02M | Put options by funds: $11.5M
26% less capital invested
Capital invested by funds: $2.65B [Q3] → $1.97B (-$688M) [Q4]
50% less funds holding in top 10
Funds holding in top 10: 2 [Q3] → 1 (-1) [Q4]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
HC Wainwright & Co. Emily Bodnar 18% 1-year accuracy 29 / 157 met price target | 81%upside $58 | Buy Reiterated | 24 Feb 2025 |
Financial journalist opinion
Based on 8 articles about AGIO published over the past 30 days
